2 Pharma Giants With Momentum That Could Carry Through 2030
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) stocks have bucked the bear market trend so far this year, gaining 6% and 20% respectively, compared to the S&P 500's loss of more than 17%. These two pharmaceutical giants, which each bring in over $20 billion in annual revenue, are evidence that as inflation wreaks havoc on consumer spending habits, healthcare remains a necessity.
After strong first-quarter earnings reports, followed by bullish comments from analysts, there is more reason to like these stocks as part of a long-term investment strategy. Can anything slow down the momentum at this point?
Image source: Getty Images.
Source Fool.com
